Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 7;7(8):1161–1179. doi: 10.1038/s41564-022-01143-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a–c, Sensitivity of B.1, Omicron BA.1, BA.1.1 and BA.2 to neutralization by sera elicited following third dose booster vaccination. a, All third dose sera irrespective of vaccine type. Each point represents the mean of three technical replicates, bar represents the mean. Group means compared by one-way ANOVA, Tukey’s multiple comparisons test; ****P < 0.0001. b, Neutralizing activity between matched second and third dose vaccine sera. Box and whisker plots (median and range). c, Comparison of matched sera after second or third dose vaccination. Each point represents the mean of three technical replicates ± s.e.m. d,e, Activity of Ronapreve (casirivimab and imdevimab) (d) and Xevudy (sotrovimab) (e) against pseudotypes bearing B.1, BA.1, BA.1.1, BA.2 and SARS-CoV-1 spike glycoproteins. Each point represents the mean of three technical replicates ± s.e.m. CPS, counts per second. f, Interferon-ɣ production by PBMC from vaccinated individuals in response to B.1 or BA.1 S-derived peptides. Dose 3 boost with BNT162b2 (circles) or mRNA-1273 (squares).

Source data